We are live on ! Find out more
CGEM icon

Cullinan Oncology
CGEM

66 hedge funds and large institutions have $762M invested in Cullinan Oncology in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 33 increasing their positions, 11 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 11

3.67% more ownership

Funds ownership: 74.11% → 77.77% (+3.7%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

4% less capital invested

Capital invested by funds: $795M → $762M (-$32.7M)

7% less funds holding

Funds holding: 71 → 66 (-5)

42% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 12

Holders
66
Holders Change
-5
Holders Change %
-7.04%
% of All Funds
1.16%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
7
Increased
33
Reduced
11
Closed
12
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$30.1M
2
BlackRock
BlackRock
New York
+$18.4M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$14M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.04M
5
Goldman Sachs
Goldman Sachs
New York
+$3.88M

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$7.61M
2
VA
VR Adviser
New York
-$7.22M
3
MB
MPM BioImpact
Massachusetts
-$7.1M
4
PVI
Pura Vida Investments
New York
-$4.26M
5
EP
Eversept Partners
New York
-$4.22M
Name Holding Trade Value Shares
Change 		Change in
Stake
MB
1
MPM BioImpact
Massachusetts
$173M -$7.1M -265,619 -3%
FCMV
2
Foresite Capital Management V
California
$61.6M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$56.4M +$14M +522,305 +26%
Vanguard Group
4
Vanguard Group
Pennsylvania
$51.5M +$30.1M +1,125,686 +97%
CA
5
CHI Advisors
New York
$50.7M +$53.5K +2,000 +0.1%
BG
6
Baupost Group
Massachusetts
$40.2M – – –
BlackRock
7
BlackRock
New York
$36.8M +$18.4M +687,316 +73%
EAM
8
Eventide Asset Management
Massachusetts
$31.7M – – –
AIG
9
American International Group
New York
$27.9M +$181K +6,756 +0.5%
O
10
OrbiMed
New York
$25.9M – – –
RSCM
11
Rock Springs Capital Management
Maryland
$24.3M – – –
BC
12
Boxer Capital
California
$24.2M – – –
DM
13
Deerfield Management
New York
$23.6M – – –
Franklin Resources
14
Franklin Resources
California
$17.5M -$29.2K -1,092 -0.1%
BI
15
BVF Inc
California
$16.6M – – –
VA
16
VR Adviser
New York
$15.9M -$7.22M -270,095 -28%
WP
17
Woodline Partners
California
$10.7M -$2.3M -86,148 -15%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$9.51M +$5.04M +188,316 +81%
State Street
19
State Street
Massachusetts
$8.19M +$3.61M +135,116 +59%
RCM
20
RA Capital Management
Massachusetts
$7.9M – – –
LGM
21
Logos Global Management
California
$6.51M – – –
Northern Trust
22
Northern Trust
Illinois
$5.17M +$2.58M +96,629 +73%
Millennium Management
23
Millennium Management
New York
$4.67M -$712K -26,631 -11%
N
24
Nuveen
North Carolina
$4.36M +$1.87M +69,822 +57%
Charles Schwab
25
Charles Schwab
California
$3.85M +$2.17M +81,045 +90%
1
2 3 4

CGEM Hedge Fund Activity: Q3 2021 in Review

66 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q3 2021, worth a combined $762M — down 4.1% from $795M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of CGEM and 7 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 33 added.

The largest buyer was Vanguard Group, adding an estimated $30.1M. The largest seller was Ikarian Capital, exiting entirely with an estimated $7.61M sold.

  • 66 institutional investors held Cullinan Oncology (CGEM) as of Q3 2021, down from 71 in Q2 2021.
  • Funds reported $762M of Cullinan Oncology stock for Q3 2021, down 4.1% quarter-over-quarter.
  • 7 funds opened new Cullinan Oncology positions in Q3 2021 and 12 closed out, a net change of -5 holders.
  • The largest Cullinan Oncology buyer in Q3 2021 was Vanguard Group, an estimated $30.1M added.
  • The largest Cullinan Oncology seller in Q3 2021 was Ikarian Capital, an estimated $7.61M sold.

Based on aggregated 13F filings for Q3 2021.